Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-11-30
2002-09-24
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S04400A, C514S825000, C514S886000
Reexamination Certificate
active
06455497
ABSTRACT:
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
Funding for the work described herein was provided by the federal government, which may have certain rights in the invention.
BACKGROUND
1. Technical Field
The invention relates to methods and materials involved in the treatment of inflammatory disease such as rheumatoid arthritis. In addition, the invention relates to reagents that reduce inflammation as well as animal models for identifying such reagents.
2. Background Information
Rheumatoid arthritis (RA) is a systemic inflammatory disease that preferentially affects the synovial membrane and leads to irreversible damage of cartilage and bone. CD4
+
T cells are the dominant cell type in the inflammatory infiltrates that together with the genetic association to MHC class II molecules has been taken as evidence for a central role of T cells in the pathogenesis of the disease (Harris ED Jr, W. B. Saunders (1997)). Tissue infiltrating CD4
+
T cells display multiple properties suggestive for local antigen recognition, such as expression of IL-2 receptors and clonal proliferation in the joint (Goronzy J J and Weyand C M,
Rheum. Dis. Clin. North Am
. 21:655-675 (1995)). Further support for in situ T cell activation has come from the structural organization of T and B cells in the inflamed synovia. In fact, T and B cells have a tendency to form aggregates that morphologically and functionally resemble germinal centers (Kurosaka M and Ziff M,
J. Exp. Med
158:1191-1210 (1983) and Schroder A E et al.,
Pro. NatL. Acad. Sci. U.S.A
. 93:221-225 (1996)). Studies on T cell derived cytokines, however, have uniformly demonstrated that T cell products are particularly scarce in rheumatoid synovitis (Firestein G S and Zvaifler N J,
Arthritis Rheum
. 33:768-773 (1990) and Feldman M et al.,
Cell
85:307-310 (1996)). The paucity of IL-2- and interferon-&ggr;(IFN-&ggr;)- producing T cells in the synovial lesions has remained an enigma.
Interleukin-16 (IL-16), originally described as a lymphocyte chemoattractant factor, is a natural ligand of the CD4 molecule (Center D M and W Cruikshank,
J. Immunol
. 128:-2563-2568 (1982); Cruikshank W W et al.,
J. Immunol
. 146:2929-2934 (1991); Cruikshank W W et al.,
Proc. Natl. Acad. Sci. U.S.A
. 91:5109-5113 (1994); and Ryan T C et al.,
J. Biol. Chem
. 270:17081-17086 (1995)). In fact, IL-16 is a pro-inflammatory cytokine that interacts with CD4 molecules and induces chemotaxis as well as IL-2 receptor and HLA-DR expression (Center D M et al., Int.
J. Biochem. Cell Biol
. 29:1231-1234 (1997)). Further, IL-16 is synthesized as a precursor protein, pro-IL-16, with CD8
+
, but not CD4
+
, T cells having the ability to secrete the bioactive form.
SUMMARY
The invention provides methods and materials for treating inflammatory diseases. Specifically, the invention provides methods and materials that reduce expression of an inflammatory cytokine such as IFN-&ggr;, IL-1&bgr;, and TNF-&agr; within inflamed tissue. For example, IL-16 polypeptide, IL-16-encoding nucleic acid, and/or an IL-16-mimicking molecule can be administered to a host such that production of an inflammatory cytokine is reduced. Alternatively, cells such as synovial tissue-derived CD8
+
T cells can be administered to a host containing inflamed tissue such that production of an inflammatory cytokine is reduced. It is noted that the IL-16 polypeptide, IL-16-encoding nucleic acid, IL-16-mimicking molecule, and/or cells can be administered with an immunosuppressive cytokine polypeptide, immunosuppressive cytokine-encoding nucleic acid, immunosuppressive cytokine-mimicking molecule, and/or cells expressing an immunosuppressive cytokine. Examples of immunosuppressive cytokines include, without limitation, TGF-&bgr;1, IL-4, and IL-10. The invention also provides methods and materials for identifying reagents that can be used to treat inflammatory diseases. Specifically, the invention provides non-human animals containing human synovial tissue as well as methods for using such non-human animals to determine the influence of various test reagents on the inflamed state of human synovial tissue.
One aspect of the invention features a method for treating an inflammatory disease (e.g., rheumatoid arthritis). The method includes identifying a host having inflamed tissue, and administering a pharmaceutically effective amount of an IL-16 polypeptide or an IL-16-mimicking molecule to the host under conditions such that the expression of an inflammatory cytokine (e.g., IFN-&ggr;, IL-1&bgr;, and TNF-&agr;) in the region of the inflamed tissue is reduced. The host is in need of an anti-inflammatory treatment and can be a mammal (e.g., a human). The IL-16 polypeptide can be recombinant human IL-16, and the IL-16-mimicking molecule can be a recombinant HIV gp120 polypeptide. The method also can include administering, to the host, a polypeptide such as TGF-&bgr;1, IL-4 and/or IL-10.
In another embodiment, the invention features a method for treating an inflammatory disease (e.g., rheumatoid arthritis) in a host. The method includes providing nucleic acid to the host. The nucleic acid encodes an IL-16 polypeptide, and the host expresses the IL-16 polypeptide from the nucleic acid such that the expression of an inflammatory cytokine (e.g., IFN-&ggr;, IL-1&bgr;, and TNF-&agr;) is reduced in the host. The host can be a mammal (e.g., a human). The IL-16 polypeptide can be human IL-16. The method also can include providing a second nucleic acid to the host. The second nucleic acid encodes an immunosuppressive cytokine (e.g., TGF-&bgr;1, IL-4, or IL-10).
Another embodiment of the invention features a method for treating an inflammatory disease (e.g., rheumatoid arthritis) in a host. The method includes administering, to the host, cells that reduce the expression of an inflammatory cytokine (e.g., IFN-&ggr;, IL-1&bgr;, and TNF-&agr;). The host can be a mammal (e.g., a human). The cells can be, for example, synovial tissue-derived CD8
+
T cells, cells that express IL-16 and/or TGF-&agr;, and/or cells containing exogenous nucleic acid encoding an IL-16 polypeptide. The IL-16 can be human IL-16. The cells can contain exogenous nucleic acid that encodes a polypeptide such as TGF-&bgr;1, IL-4, and/or IL-10. In addition, the cells can have specificity for a synovial antigen, and can accumulate within synovial tissue.
In another aspect, the invention features a pharmaceutical composition for treating an inflammatory disease (e.g., rheumatoid arthritis) in a host. The composition contains an IL-16 polypeptide (e.g., recombinant human IL-16) or an IL-16-mimicking molecule (e.g., a recombinant HIV gp120 polypeptide) and an immunosuppressive cytokine (e.g., TGF-&bgr;1, IL-4, and IL-10). The administration of the composition to the host reduces the expression of an inflammatory cytokine (e.g., IFN-&ggr;, IL-1&bgr;, and TNF-&agr;) in the host. The host can be a mammal (e.g., a human).
Another aspect of the invention features a non-human animal containing human synovial tissue. The non-human animal can be a murine animal. In addition, the non-human animal can be immunocompromised. For example, the immunocompromised non-human animal can be a SCID mouse or a recombination-activating gene-deficient animal. At least a portion of the human synovial tissue can be located under the skin and/or in the back region of the non-human animal. The human synovial tissue can be inflamed human synovial tissue. The inflamed human synovial tissue can be in a diffuse and/or follicular state of inflammation within the animal. The human synovial tissue can be diffusely vascularized human synovial tissue within the animal. The non-human animal can be a NOD/LtSz-Prkdc
scid
/J mouse having human synovial tissue derived from a rheumatoid arthritis patient.
Another aspect of the invention features a method for identifying a treatment reagent that reduces inflammation. The method includes administering a test reagent to a non-human animal having human synovial tissue, at least a portion of the human synovial tissue being inflamed, an
Goronzy Jorg J.
Weyand Cornelia M.
Fish & Richardson P.C. P.A.
Mayo Foundation for Medical Education and Research
Weddington Kevin E.
LandOfFree
Methods and materials for treating inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and materials for treating inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for treating inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2822253